Celldex Therapeutics, Inc. Stock Deutsche Boerse AG
Stocks
US15117B1035
Biotechnology & Medical Research
| Market Cap | 2.59B 2.28B 2.1B 1.97B 3.68B 245B 3.75B 25.22B 9.76B 120B 9.72B 9.51B 419B | P/E 2026 * |
-7.79x | P/E 2027 * | -7.73x |
|---|---|---|---|---|---|
| Enterprise Value | 2B 1.77B 1.63B 1.52B 2.85B 190B 2.91B 19.53B 7.56B 93.07B 7.53B 7.36B 324B | EV / Sales 2026 * |
761x | EV / Sales 2027 * | 174x |
| Free-Float |
99.73% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Celldex Therapeutics, Inc.
| 1 day | +2.56% |
| Manager | Title | Age | Since |
|---|---|---|---|
Tibor Keler
CTO | Chief Tech/Sci/R&D Officer | 67 | 30/07/2014 |
Anthony Marucci
CEO | Chief Executive Officer | 64 | 01/09/2008 |
Sam Martin
DFI | Director of Finance/CFO | 55 | 01/04/2009 |
| Director | Title | Age | Since |
|---|---|---|---|
Anthony Marucci
BRD | Director/Board Member | 64 | 01/12/2008 |
Harry Penner
CHM | Chairman | 80 | 05/06/2025 |
Herbert Conrad
BRD | Director/Board Member | 93 | 01/03/2008 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +2.56% | +823.22% | - | - | 2.59B | |
| +2.56% | +6.88% | -5.81% | -0.26% | 44.45B | |
| +0.15% | +8.42% | +324.00% | +565.24% | 36.04B | |
| +0.36% | +5.00% | +7.62% | +54.57% | 30.7B | |
| +8.37% | +3.60% | +19.62% | -13.29% | 28.59B | |
| +7.60% | -1.03% | +14.05% | +20.82% | 23.01B | |
| -0.24% | +2.95% | - | - | 14.82B | |
| +8.30% | +11.09% | +66.15% | +129.55% | 13.52B | |
| +2.73% | +6.86% | +12.60% | +18.45% | 12.98B | |
| +0.70% | +4.69% | +103.13% | +93.04% | 12.56B | |
| Average | +3.31% | +2.88% | +67.67% | +108.52% | 24.07B | |
| Weighted average by Cap. | +3.21% | +3.11% | +73.77% | +125.31% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 2.63M 2.32M 2.14M 2M 3.75M 249M 3.82M 25.66M 9.93M 122M 9.89M 9.68M 426M | 11.96M 10.54M 9.72M 9.09M 17.03M 1.13B 17.35M 117M 45.11M 555M 44.91M 43.93M 1.94B |
| Net income | -330M -291M -268M -251M -470M -31.24B -479M -3.21B -1.24B -15.33B -1.24B -1.21B -53.39B | -370M -326M -301M -281M -527M -35.07B -537M -3.61B -1.4B -17.2B -1.39B -1.36B -59.93B |
| Net Debt | -584M -514M -475M -444M -831M -55.29B -847M -5.69B -2.2B -27.12B -2.19B -2.15B -94.49B | -507M -447M -412M -385M -722M -48.03B -736M -4.94B -1.91B -23.56B -1.9B -1.86B -82.08B |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
